{"url":"https://newsforagent.com/news/2026-10-19/gradientech-quickmic-gn02-cefiderocol-panel","markdown_url":"https://newsforagent.com/news/2026-10-19/gradientech-quickmic-gn02-cefiderocol-panel.md","title":"Gradientech Launches QuickMIC GN02 Cefiderocol Panel","headline":"Gradientech Launches QuickMIC GN02 Panel for Cefiderocol Susceptibility in 3 Hours 14 Minutes","description":"Gradientech launched QuickMIC GN02, an IVDR CE-marked AST panel that returns cefiderocol susceptibility results in 3 hours 14 minutes.","section":"Product Launches","published_at":"2026-10-19T07:37:11+00:00","modified_at":"2026-10-19T07:37:11+00:00","author":"News Desk","key_takeaways":["Gradientech launched QuickMIC GN02, an IVDR CE-marked AST panel that delivers cefiderocol susceptibility results in 3 hours and 14 minutes.","The panel recorded 95.5% essential agreement, 96.0% categorical agreement, 98.9% reproducibility and 99.6% of quality control results within range.","QuickMIC holds Breakthrough Device designation from the U.S. Food and Drug Administration and is available for Investigational Use Only in the U.S., but is not 510(k) cleared."],"companies":[{"name":"Gradientech","is_primary":true,"profile_url":"https://akta.pro/company-profiles/0000edd/gradientech","website":"http://gradientech.se"}],"source":{"publisher":"news.cision.com","title":"Gradientech Brings Cefiderocol to Rapid AST in Just Over 3 Hours","url":"https://news.cision.com/gradientech-ab/r/gradientech-brings-cefiderocol-to-rapid-ast-in-just-over-3-hours,c4411427"},"other_sources":[],"tags":["Product Launches","Gradientech"],"body_markdown":"[Gradientech](https://akta.pro/company-profiles/0000edd/gradientech) launched QuickMIC GN02, an IVDR CE-marked antibiotic susceptibility testing panel that returns cefiderocol susceptibility results for challenging Gram-negative pathogens in 3 hours and 14 minutes, [news.cision.com](https://news.cision.com/gradientech-ab/r/gradientech-brings-cefiderocol-to-rapid-ast-in-just-over-3-hours,c4411427) reported on October 19, 2026. The panel adds cefiderocol and other reserve antibiotics to the QuickMIC portfolio.\n\n## What the QuickMIC GN02 Panel Tests\n\nThe panel is built for multidrug-resistant Gram-negative bacteria, the pathogens behind bloodstream infections and sepsis, and it is aimed at hospital microbiology laboratories that need susceptibility answers within a single rapid workflow. Gradientech said the evaluation produced 95.5% essential agreement, 96.0% categorical agreement, 98.9% reproducibility and 99.6% of quality control results within range, which it said exceeds regulatory performance requirements.\n\n\"QuickMIC GN02 represents a significant expansion of our rapid AST capabilities. Bringing cefiderocol into a rapid AST workflow is an important technical achievement, and we are proud to make this capability available to laboratories,\" said Christer Malmberg, CSO at Gradientech. \"It expands the clinical value of our QuickMIC platform and, importantly, gives laboratories more opportunities to deliver actionable results within the same rapid workflow.\"\n\n\"For me, this is also about what we are building as a company,\" said Sumi Thaker, CEO of Gradientech. \"We want QuickMIC to become a trusted solution for laboratories facing increasingly complex resistance patterns. The team has made real progress, and I look forward to bringing this capability to more laboratories and clinicians.\"\n\nThe QuickMIC system is CE marked and commercially available in Europe. It has been granted Breakthrough Device designation by the U.S. Food and Drug Administration and is available for Investigational Use Only in the U.S., but not 510(k) cleared. The FDA granted Fast Track designation to PureTech's LYT-200 in combination with a hypomethylating agent for relapsed or refractory high-risk myelodysplastic syndromes, [FinancialContent Business Page](https://akta.pro/news-signals) reported on September 21, 2026.\n\n## Gradientech's Funding and European Footprint\n\nGradientech completed a rights issue in March 2026, with 5,619,127 shares subscribed, about 87 percent of the offering, raising approximately SEK 49.2 million before issue costs, of which SEK 14 million offset loans, according to akta.pro [company records](https://akta.pro/company-data). The same records list 16 European hospitals operating QuickMIC in routine use or advanced implementation as of year-end 2025, with expected annual test volumes typically in the several-hundred range and scaling beyond 1,000 tests per site. Net sales for full year 2025 were SEK 5,889 thousand, up from SEK 4,457 thousand in 2024, and the net loss for 2025 was SEK -72,284 thousand, compared with SEK -63,620 thousand in 2024.\n\n## Gradientech's Distribution Agreements\n\nGradientech signed an exclusive Greek distribution agreement with ELTA 90 MGR in February 2026 for commercialization of QuickMIC in Greece, and a long-term agreement with ELBLAB GmbH in Germany for deployment of the QuickMIC system in clinical workflows at its microbiology laboratory for critically ill patients, including those with sepsis or severe pneumonia.\n","publisher":{"name":"News for Agent","url":"https://newsforagent.com"}}